Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 16, 2024European Journal of Microbiology and ImmunologyOpen Access

Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine

View Full Paper
Ask AI
Bookmark
Share

Authors

NDNavid DashtiFGForough Golsaz‐ShiraziHSHaleh Soltanghoraee

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Dashti et al. (2024) studied this question.

synapsesocial.com/papers/68e69b09b6db643587620e95https://doi.org/10.1556/1886.2024.00045
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China2020 · 281 citations
  2. 2COVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough2021 · 207 citations
  3. 3Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-4522021 · 45 citations
  4. 4CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-22023 · 10 citations
  5. 5COVID-19 Vaccines: Where Did We Stand at the End of 2023?2024 · 17 citations